Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma

• Published in: Molecular cancer 2024-01, Vol.23 (1), p.12-12, Article 12
• Main Authors: Fang, XiaoChang, Shu, Lin, Chen, TianLiang, Zhao, XiaoLe, Yang, LiuCui, Dou, Tingting, Yang, Lijie, Li, Xuanfei, Feng, Maohui
• Format: Article
• Language: English
• Subjects: Abdomen; Analysis; Animals; Disease Models, Animal; DNA sequencing; Drug screening; Ethylenediaminetetraacetic acid; Genomes; Genomics; Histopathology; Humans; Malignant peritoneal Mesothelioma; Medical prognosis; Medical research; Medicine, Experimental; Mesothelioma; Mesothelioma, Malignant; Mesylates; Nucleotide sequencing; Organoids; Patient-derived organoids (PDO); Patient-derived organoids xenograft (PDOX); Patients; Penicillin; Peritoneal Neoplasms - drug therapy; Peritoneal Neoplasms - genetics; Peritoneal orthotopic xenograft; Peritoneum; Piperidines; Primary cell lines; Prognosis; R&D; Research & development; Retrospective Studies; Tumors; Whole genome sequencing; Xenografts
• ISSN: 1476-4598; 1476-4598
• DOI: 10.1186/s12943-023-01901-z

Malignant peritoneal mesothelioma (MPM) is an extremely rare and highly invasive tumor. Due to the lack of accurate models that reflect the biological characteristics of primary tumors, studying MPM remains challenging and is associated with an exceedingly unfavorable prognosis. This study was aimed to establish a new potential preclinical model for MPM using patient-derived MPM organoids (MPMOs) and to comprehensively evaluate the practicality of this model in medical research and its feasibility in guiding individualized patient treatment. MPMOs were constructed using tumor tissue from MPM patients. Histopathological analysis and whole genome sequencing (WGS) were employed to determine the ability of MPMOs to replicate the original tumor's genetic and histological characteristics. The subcutaneous and orthotopic xenograft models were employed to assess the feasibility of establishing an in vivo model of MPM. MPMOs were also used to conduct drug screening and compare the results with retrospective analysis of patients after treatment, in order to evaluate the potential of MPMOs in predicting the effectiveness of drugs in MPM patients. We successfully established a culture method for human MPM organoids using tumor tissue from MPM patients and provided a comprehensive description of the necessary medium components for MPMOs. Pathological examination and WGS revealed that MPMOs accurately represented the histological characteristics and genomic heterogeneity of the original tumors. In terms of application, the success rate of creating subcutaneous and orthotopic xenograft models using MPMOs was 88% and 100% respectively. Drug sensitivity assays demonstrated that MPMOs have different medication responses, and these differences were compatible with the real situation of the patients. This study presents a method for generating human MPM organoids, which can serve as a valuable research tool and contribute to the advancement of MPM research. Additionally, these organoids can be utilized as a means to evaluate the effectiveness of drug treatments for MPM patients, offering a model for personalized treatment approaches.